Inadequate responses to hepatitis B vaccine occur in approximately 5-15% of neonates. Factors that influence the response to vaccination include the immunogenetic state of the vaccine recipient: carriers of the human leucocyte antigen (HLA)-B8, DR3 do not develop adequate responses to hepatitis B vaccine 1. To determine the importance of the immunogenetic factor for the outcome of hepatitis B vaccination in neonates, we investigated the HLA type of infants with an inadequate response to hepatitis B vaccination and analysed the subgroups non-infected low responders and infected non-responders for differences in the specific HLA type.
Between 1982 and 1991, 705 healthy newborns from HBsAg-positive mothers received HBIg at birth and were vaccinated within the first year with plasma or recombinant-DNA vaccine according to a three-or four-dose vaccination schedule 2. During the first year blood was assayed for HBsAg and anti-HBs (IU/1) at 3, 6, 11 and 12 months of age. Sixteen of the 705 newborns (2.3%) with anti-HBs titres < 10 IU/1 were identified; eight infants with an anti-HBs level below 10IU/I and negative tests for HBsAg (non-infected low responders ) and another eight infants who became anti-HBs negative but HBsAg-positive (infected non-responders).
HLA typing for class I and II antigens was performed, using standard microcytotoxicity test on peripheral blood mononuclear cells. the eight infected non-responders to hepatitis B vaccine. HLA-DR3 was present in four of the eight (50%; 95% CI: 15-85% ) non-infected low responders and in none of the eight (0%) infected non-responders. Two non-infected low responders were probably homozygous for HLA-DR3.
This study confirms that the HLA-DR3 haplotype plays a role in the low responsiveness to hepatitis B vaccination in non-infected neonates. In our study with only a small number of ethnically heterozygous individuals, all four DR3-positive children were non-infected low responders and two of them were probably homozygous for DR3. These low responders were not absolute non-responders, since all of them developed protective anti-HBs levels after hepatitis B revaccination in their second year of life 3. The two children homozygous for HLA-DR3 produced anti-HBs in the lowest range (45 and 55 IU/1, respectively) after revaccination in comparison to the other six revaccinated low responders (median 171, range 49-3497IU/1). The observation that none of the eight non-responders, who became infected with hepatitis B virus, was DR3-positive suggests that HLAassociated low responsiveness is not causally related to this type of failure of hepatitis B vaccination.
